Artificial Pancreas Systems for People With Type 2 Diabetes: Conception and Design of the European CLOSE Project
In the last 10 years tremendous progress has been made in the development of artificial pancreas (AP) systems for people with type 1 diabetes (T1D). The pan-European consortium CLOSE (Automated Glucose Control at Home for People with Chronic Disease) is aiming to develop integrated AP solutions (APp...
Gespeichert in:
| Veröffentlicht in: | Journal of Diabetes Science and Technology 2019-03, Vol.13 (2), p.261-267 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 267 |
|---|---|
| container_issue | 2 |
| container_start_page | 261 |
| container_title | Journal of Diabetes Science and Technology |
| container_volume | 13 |
| creator | Schliess, Freimut Heise, Tim Benesch, Carsten Mianowska, Beata Stegbauer, Constance Broge, Björn Gillard, Pieter Binkley, George Crône, Véronique Carlier, Sébastien Delval, Cécile Petkov, Anton Beck, Jan-Philipp Lodwig, Volker Gurdala, Mikolaj Szecsenyi, Joachim Rosenmöller, Magda Cypryk, Katarzyna Mathieu, Chantal Renard, Eric Heinemann, Lutz |
| description | In the last 10 years tremendous progress has been made in the development of artificial pancreas (AP) systems for people with type 1 diabetes (T1D). The pan-European consortium CLOSE (Automated Glucose Control at Home for People with Chronic Disease) is aiming to develop integrated AP solutions (APplus) tailored to the needs of people with type 2 diabetes (T2D). APplus comprises a product and service package complementing the AP system by obligatory training as well as home visits and telemedical consultations on demand. Outcome predictors and performance indicators shall help to identify people who could benefit most from AP usage and facilitate the measurement of AP impact in diabetes care. In a first step CLOSE will establish a scalable APplus model case working at the interface between patients, homecare service providers, and payers in France. CLOSE will then scale up APplus by pursuing geographic distribution, targeting additional audiences, and enhancing AP functionalities and interconnectedness. By being part of the European Institute of Innovation and Technology (EIT) Health public-private partnership, CLOSE is committed to the EIT “knowledge triangle” pursuing the integrated advancement of technology, education, and business creation. Putting stakeholders, education, and impact into the center of APplus advancement is considered key for achieving wide AP use in T2D care. |
| doi_str_mv | 10.1177/1932296818803588 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6399797</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1932296818803588</sage_id><sourcerecordid>2111148209</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3838-31db30e446c6799da23e2a4425d42073620c2f45f005a0ffff9dd782ccb7cbd3</originalsourceid><addsrcrecordid>eNp1UU1rGzEUXEpDkya991R0bA_b6ssrqYeCcdymYIghhhyFVvvWlllLW2k34H9fLU5CGui7PDFvZqSnKYqPBH8lRIhvRDFKVSWJlJjNpHxTXExQOWFvX5zPi_cp7TGecSnEu-KcYcoJ5_yi6OdxcK2zznRobbyNYBK6O6YBDgm1IaI1hL4DdO-GHdoce0AUXTtTwwDpO1oEb6EfXPDI-AZdQ3Jbj0KLhh2g5RhDD8ajxer2bonWMezBDlfFWWu6BB8e-2Wx-bncLG7K1e2v34v5qrRMMlky0tQMA-eVrYRSjaEMqOGczhpOsWAVxZa2fNbmpQxuc6mmEZJaWwtbN-yy-HGy7cf6AI0FP0TT6T66g4lHHYzT_0682-lteNAVU0ookQ2-nAx2r2Q385WeMDw9gxL6QDL38-NlMfwZIQ364JKFrjMewpg0Jbm4pFhlKj5RbQwpRWifvQnWU6b6daZZ8unlKs-CpxAzoTwRktmC3ocx-vyz_zf8CzHSqMI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2111148209</pqid></control><display><type>article</type><title>Artificial Pancreas Systems for People With Type 2 Diabetes: Conception and Design of the European CLOSE Project</title><source>Access via SAGE</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Schliess, Freimut ; Heise, Tim ; Benesch, Carsten ; Mianowska, Beata ; Stegbauer, Constance ; Broge, Björn ; Gillard, Pieter ; Binkley, George ; Crône, Véronique ; Carlier, Sébastien ; Delval, Cécile ; Petkov, Anton ; Beck, Jan-Philipp ; Lodwig, Volker ; Gurdala, Mikolaj ; Szecsenyi, Joachim ; Rosenmöller, Magda ; Cypryk, Katarzyna ; Mathieu, Chantal ; Renard, Eric ; Heinemann, Lutz</creator><creatorcontrib>Schliess, Freimut ; Heise, Tim ; Benesch, Carsten ; Mianowska, Beata ; Stegbauer, Constance ; Broge, Björn ; Gillard, Pieter ; Binkley, George ; Crône, Véronique ; Carlier, Sébastien ; Delval, Cécile ; Petkov, Anton ; Beck, Jan-Philipp ; Lodwig, Volker ; Gurdala, Mikolaj ; Szecsenyi, Joachim ; Rosenmöller, Magda ; Cypryk, Katarzyna ; Mathieu, Chantal ; Renard, Eric ; Heinemann, Lutz</creatorcontrib><description>In the last 10 years tremendous progress has been made in the development of artificial pancreas (AP) systems for people with type 1 diabetes (T1D). The pan-European consortium CLOSE (Automated Glucose Control at Home for People with Chronic Disease) is aiming to develop integrated AP solutions (APplus) tailored to the needs of people with type 2 diabetes (T2D). APplus comprises a product and service package complementing the AP system by obligatory training as well as home visits and telemedical consultations on demand. Outcome predictors and performance indicators shall help to identify people who could benefit most from AP usage and facilitate the measurement of AP impact in diabetes care. In a first step CLOSE will establish a scalable APplus model case working at the interface between patients, homecare service providers, and payers in France. CLOSE will then scale up APplus by pursuing geographic distribution, targeting additional audiences, and enhancing AP functionalities and interconnectedness. By being part of the European Institute of Innovation and Technology (EIT) Health public-private partnership, CLOSE is committed to the EIT “knowledge triangle” pursuing the integrated advancement of technology, education, and business creation. Putting stakeholders, education, and impact into the center of APplus advancement is considered key for achieving wide AP use in T2D care.</description><identifier>ISSN: 1932-2968</identifier><identifier>EISSN: 1932-2968</identifier><identifier>EISSN: 1932-3107</identifier><identifier>DOI: 10.1177/1932296818803588</identifier><identifier>PMID: 30241444</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Animals ; Biomarkers ; Blood Glucose - drug effects ; Blood Glucose - metabolism ; Blood Glucose Self-Monitoring - instrumentation ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - diagnosis ; Diabetes Mellitus, Type 2 - drug therapy ; Equipment Design ; Europe ; Humans ; Insulin Infusion Systems - adverse effects ; Life Sciences ; Pancreas, Artificial - adverse effects ; Research Design ; Review ; Stakeholder Participation ; Treatment Outcome</subject><ispartof>Journal of Diabetes Science and Technology, 2019-03, Vol.13 (2), p.261-267</ispartof><rights>2018 Diabetes Technology Society</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><rights>2018 Diabetes Technology Society 2018 Diabetes Technology Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3838-31db30e446c6799da23e2a4425d42073620c2f45f005a0ffff9dd782ccb7cbd3</citedby><cites>FETCH-LOGICAL-c3838-31db30e446c6799da23e2a4425d42073620c2f45f005a0ffff9dd782ccb7cbd3</cites><orcidid>0000-0001-6377-2751 ; 0000-0003-2493-1304 ; 0000-0002-3407-7263</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399797/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399797/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,313,314,727,780,784,792,885,21819,27922,27924,27925,43621,43622,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30241444$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.umontpellier.fr/hal-02073212$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Schliess, Freimut</creatorcontrib><creatorcontrib>Heise, Tim</creatorcontrib><creatorcontrib>Benesch, Carsten</creatorcontrib><creatorcontrib>Mianowska, Beata</creatorcontrib><creatorcontrib>Stegbauer, Constance</creatorcontrib><creatorcontrib>Broge, Björn</creatorcontrib><creatorcontrib>Gillard, Pieter</creatorcontrib><creatorcontrib>Binkley, George</creatorcontrib><creatorcontrib>Crône, Véronique</creatorcontrib><creatorcontrib>Carlier, Sébastien</creatorcontrib><creatorcontrib>Delval, Cécile</creatorcontrib><creatorcontrib>Petkov, Anton</creatorcontrib><creatorcontrib>Beck, Jan-Philipp</creatorcontrib><creatorcontrib>Lodwig, Volker</creatorcontrib><creatorcontrib>Gurdala, Mikolaj</creatorcontrib><creatorcontrib>Szecsenyi, Joachim</creatorcontrib><creatorcontrib>Rosenmöller, Magda</creatorcontrib><creatorcontrib>Cypryk, Katarzyna</creatorcontrib><creatorcontrib>Mathieu, Chantal</creatorcontrib><creatorcontrib>Renard, Eric</creatorcontrib><creatorcontrib>Heinemann, Lutz</creatorcontrib><title>Artificial Pancreas Systems for People With Type 2 Diabetes: Conception and Design of the European CLOSE Project</title><title>Journal of Diabetes Science and Technology</title><addtitle>J Diabetes Sci Technol</addtitle><description>In the last 10 years tremendous progress has been made in the development of artificial pancreas (AP) systems for people with type 1 diabetes (T1D). The pan-European consortium CLOSE (Automated Glucose Control at Home for People with Chronic Disease) is aiming to develop integrated AP solutions (APplus) tailored to the needs of people with type 2 diabetes (T2D). APplus comprises a product and service package complementing the AP system by obligatory training as well as home visits and telemedical consultations on demand. Outcome predictors and performance indicators shall help to identify people who could benefit most from AP usage and facilitate the measurement of AP impact in diabetes care. In a first step CLOSE will establish a scalable APplus model case working at the interface between patients, homecare service providers, and payers in France. CLOSE will then scale up APplus by pursuing geographic distribution, targeting additional audiences, and enhancing AP functionalities and interconnectedness. By being part of the European Institute of Innovation and Technology (EIT) Health public-private partnership, CLOSE is committed to the EIT “knowledge triangle” pursuing the integrated advancement of technology, education, and business creation. Putting stakeholders, education, and impact into the center of APplus advancement is considered key for achieving wide AP use in T2D care.</description><subject>Animals</subject><subject>Biomarkers</subject><subject>Blood Glucose - drug effects</subject><subject>Blood Glucose - metabolism</subject><subject>Blood Glucose Self-Monitoring - instrumentation</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - diagnosis</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Equipment Design</subject><subject>Europe</subject><subject>Humans</subject><subject>Insulin Infusion Systems - adverse effects</subject><subject>Life Sciences</subject><subject>Pancreas, Artificial - adverse effects</subject><subject>Research Design</subject><subject>Review</subject><subject>Stakeholder Participation</subject><subject>Treatment Outcome</subject><issn>1932-2968</issn><issn>1932-2968</issn><issn>1932-3107</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><sourceid>EIF</sourceid><recordid>eNp1UU1rGzEUXEpDkya991R0bA_b6ssrqYeCcdymYIghhhyFVvvWlllLW2k34H9fLU5CGui7PDFvZqSnKYqPBH8lRIhvRDFKVSWJlJjNpHxTXExQOWFvX5zPi_cp7TGecSnEu-KcYcoJ5_yi6OdxcK2zznRobbyNYBK6O6YBDgm1IaI1hL4DdO-GHdoce0AUXTtTwwDpO1oEb6EfXPDI-AZdQ3Jbj0KLhh2g5RhDD8ajxer2bonWMezBDlfFWWu6BB8e-2Wx-bncLG7K1e2v34v5qrRMMlky0tQMA-eVrYRSjaEMqOGczhpOsWAVxZa2fNbmpQxuc6mmEZJaWwtbN-yy-HGy7cf6AI0FP0TT6T66g4lHHYzT_0682-lteNAVU0ookQ2-nAx2r2Q385WeMDw9gxL6QDL38-NlMfwZIQ364JKFrjMewpg0Jbm4pFhlKj5RbQwpRWifvQnWU6b6daZZ8unlKs-CpxAzoTwRktmC3ocx-vyz_zf8CzHSqMI</recordid><startdate>20190301</startdate><enddate>20190301</enddate><creator>Schliess, Freimut</creator><creator>Heise, Tim</creator><creator>Benesch, Carsten</creator><creator>Mianowska, Beata</creator><creator>Stegbauer, Constance</creator><creator>Broge, Björn</creator><creator>Gillard, Pieter</creator><creator>Binkley, George</creator><creator>Crône, Véronique</creator><creator>Carlier, Sébastien</creator><creator>Delval, Cécile</creator><creator>Petkov, Anton</creator><creator>Beck, Jan-Philipp</creator><creator>Lodwig, Volker</creator><creator>Gurdala, Mikolaj</creator><creator>Szecsenyi, Joachim</creator><creator>Rosenmöller, Magda</creator><creator>Cypryk, Katarzyna</creator><creator>Mathieu, Chantal</creator><creator>Renard, Eric</creator><creator>Heinemann, Lutz</creator><general>SAGE Publications</general><general>Diabetes Technology Society</general><scope>AFRWT</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6377-2751</orcidid><orcidid>https://orcid.org/0000-0003-2493-1304</orcidid><orcidid>https://orcid.org/0000-0002-3407-7263</orcidid></search><sort><creationdate>20190301</creationdate><title>Artificial Pancreas Systems for People With Type 2 Diabetes: Conception and Design of the European CLOSE Project</title><author>Schliess, Freimut ; Heise, Tim ; Benesch, Carsten ; Mianowska, Beata ; Stegbauer, Constance ; Broge, Björn ; Gillard, Pieter ; Binkley, George ; Crône, Véronique ; Carlier, Sébastien ; Delval, Cécile ; Petkov, Anton ; Beck, Jan-Philipp ; Lodwig, Volker ; Gurdala, Mikolaj ; Szecsenyi, Joachim ; Rosenmöller, Magda ; Cypryk, Katarzyna ; Mathieu, Chantal ; Renard, Eric ; Heinemann, Lutz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3838-31db30e446c6799da23e2a4425d42073620c2f45f005a0ffff9dd782ccb7cbd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animals</topic><topic>Biomarkers</topic><topic>Blood Glucose - drug effects</topic><topic>Blood Glucose - metabolism</topic><topic>Blood Glucose Self-Monitoring - instrumentation</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - diagnosis</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Equipment Design</topic><topic>Europe</topic><topic>Humans</topic><topic>Insulin Infusion Systems - adverse effects</topic><topic>Life Sciences</topic><topic>Pancreas, Artificial - adverse effects</topic><topic>Research Design</topic><topic>Review</topic><topic>Stakeholder Participation</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schliess, Freimut</creatorcontrib><creatorcontrib>Heise, Tim</creatorcontrib><creatorcontrib>Benesch, Carsten</creatorcontrib><creatorcontrib>Mianowska, Beata</creatorcontrib><creatorcontrib>Stegbauer, Constance</creatorcontrib><creatorcontrib>Broge, Björn</creatorcontrib><creatorcontrib>Gillard, Pieter</creatorcontrib><creatorcontrib>Binkley, George</creatorcontrib><creatorcontrib>Crône, Véronique</creatorcontrib><creatorcontrib>Carlier, Sébastien</creatorcontrib><creatorcontrib>Delval, Cécile</creatorcontrib><creatorcontrib>Petkov, Anton</creatorcontrib><creatorcontrib>Beck, Jan-Philipp</creatorcontrib><creatorcontrib>Lodwig, Volker</creatorcontrib><creatorcontrib>Gurdala, Mikolaj</creatorcontrib><creatorcontrib>Szecsenyi, Joachim</creatorcontrib><creatorcontrib>Rosenmöller, Magda</creatorcontrib><creatorcontrib>Cypryk, Katarzyna</creatorcontrib><creatorcontrib>Mathieu, Chantal</creatorcontrib><creatorcontrib>Renard, Eric</creatorcontrib><creatorcontrib>Heinemann, Lutz</creatorcontrib><collection>Sage Journals GOLD Open Access 2024</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of Diabetes Science and Technology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schliess, Freimut</au><au>Heise, Tim</au><au>Benesch, Carsten</au><au>Mianowska, Beata</au><au>Stegbauer, Constance</au><au>Broge, Björn</au><au>Gillard, Pieter</au><au>Binkley, George</au><au>Crône, Véronique</au><au>Carlier, Sébastien</au><au>Delval, Cécile</au><au>Petkov, Anton</au><au>Beck, Jan-Philipp</au><au>Lodwig, Volker</au><au>Gurdala, Mikolaj</au><au>Szecsenyi, Joachim</au><au>Rosenmöller, Magda</au><au>Cypryk, Katarzyna</au><au>Mathieu, Chantal</au><au>Renard, Eric</au><au>Heinemann, Lutz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Artificial Pancreas Systems for People With Type 2 Diabetes: Conception and Design of the European CLOSE Project</atitle><jtitle>Journal of Diabetes Science and Technology</jtitle><addtitle>J Diabetes Sci Technol</addtitle><date>2019-03-01</date><risdate>2019</risdate><volume>13</volume><issue>2</issue><spage>261</spage><epage>267</epage><pages>261-267</pages><issn>1932-2968</issn><eissn>1932-2968</eissn><eissn>1932-3107</eissn><abstract>In the last 10 years tremendous progress has been made in the development of artificial pancreas (AP) systems for people with type 1 diabetes (T1D). The pan-European consortium CLOSE (Automated Glucose Control at Home for People with Chronic Disease) is aiming to develop integrated AP solutions (APplus) tailored to the needs of people with type 2 diabetes (T2D). APplus comprises a product and service package complementing the AP system by obligatory training as well as home visits and telemedical consultations on demand. Outcome predictors and performance indicators shall help to identify people who could benefit most from AP usage and facilitate the measurement of AP impact in diabetes care. In a first step CLOSE will establish a scalable APplus model case working at the interface between patients, homecare service providers, and payers in France. CLOSE will then scale up APplus by pursuing geographic distribution, targeting additional audiences, and enhancing AP functionalities and interconnectedness. By being part of the European Institute of Innovation and Technology (EIT) Health public-private partnership, CLOSE is committed to the EIT “knowledge triangle” pursuing the integrated advancement of technology, education, and business creation. Putting stakeholders, education, and impact into the center of APplus advancement is considered key for achieving wide AP use in T2D care.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>30241444</pmid><doi>10.1177/1932296818803588</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-6377-2751</orcidid><orcidid>https://orcid.org/0000-0003-2493-1304</orcidid><orcidid>https://orcid.org/0000-0002-3407-7263</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-2968 |
| ispartof | Journal of Diabetes Science and Technology, 2019-03, Vol.13 (2), p.261-267 |
| issn | 1932-2968 1932-2968 1932-3107 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6399797 |
| source | Access via SAGE; MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Animals Biomarkers Blood Glucose - drug effects Blood Glucose - metabolism Blood Glucose Self-Monitoring - instrumentation Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - drug therapy Equipment Design Europe Humans Insulin Infusion Systems - adverse effects Life Sciences Pancreas, Artificial - adverse effects Research Design Review Stakeholder Participation Treatment Outcome |
| title | Artificial Pancreas Systems for People With Type 2 Diabetes: Conception and Design of the European CLOSE Project |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T13%3A20%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Artificial%20Pancreas%20Systems%20for%20People%20With%20Type%202%20Diabetes:%20Conception%20and%20Design%20of%20the%20European%20CLOSE%20Project&rft.jtitle=Journal%20of%20Diabetes%20Science%20and%20Technology&rft.au=Schliess,%20Freimut&rft.date=2019-03-01&rft.volume=13&rft.issue=2&rft.spage=261&rft.epage=267&rft.pages=261-267&rft.issn=1932-2968&rft.eissn=1932-2968&rft_id=info:doi/10.1177/1932296818803588&rft_dat=%3Cproquest_pubme%3E2111148209%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2111148209&rft_id=info:pmid/30241444&rft_sage_id=10.1177_1932296818803588&rfr_iscdi=true |